VEGFA and age-related macular degeneration: The advent of anti-VEGF therapies (i.e., bevacizumab, ranibizumab, aflibercept, and brolucizumab) helped revolutionize the treatment landscape for AMD, including neovascular AMD (nAMD), by providing patients with a safe and efficacious therapy that results in significant improvements in vision and reduced vision loss [14].